Watson DJ - Search Results

1

Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.

Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ. Watson DJ, et al. MedGenMed. 2001 Nov 16;3(4):6. MedGenMed. 2001. PMID: 11965201 Free article.

2

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. Ramey DR, et al. Among authors: watson dj. Curr Med Res Opin. 2005 May;21(5):715-22. doi: 10.1185/030079905x43686. Curr Med Res Opin. 2005. PMID: 15974563

3

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. Watson DJ, et al. Curr Med Res Opin. 2004 Oct;20(10):1539-48. doi: 10.1185/030079904x3078. Curr Med Res Opin. 2004. PMID: 15462687

4

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.

Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Ehrich EW, et al. Among authors: watson dj. J Rheumatol. 2000 Nov;27(11):2635-41. J Rheumatol. 2000. PMID: 11093446 Clinical Trial.

5

Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.

Ehrich EW, Bolognese JA, Watson DJ, Kong SX. Ehrich EW, et al. Among authors: watson dj. Am J Manag Care. 2001 Jun;7(6):609-16. Am J Manag Care. 2001. PMID: 11439734 Free article. Clinical Trial.

6

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Pellissier JM, et al. Among authors: watson dj. Clin Ther. 2001 Jul;23(7):1061-79. doi: 10.1016/s0149-2918(01)80092-8. Clin Ther. 2001. PMID: 11519771 Review.

7

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.

Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Watson DJ, et al. Curr Med Res Opin. 2004 Dec;20(12):1899-908. doi: 10.1185/030079904X12681. Curr Med Res Opin. 2004. PMID: 15701208

8

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Langman MJ, et al. Among authors: watson dj. JAMA. 1999 Nov 24;282(20):1929-33. doi: 10.1001/jama.282.20.1929. JAMA. 1999. PMID: 10580458

9

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Watson DJ, et al. Arch Intern Med. 2000 Oct 23;160(19):2998-3003. doi: 10.1001/archinte.160.19.2998. Arch Intern Med. 2000. PMID: 11041909

10

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B. Hunt RH, et al. Among authors: watson dj. Am J Gastroenterol. 2003 Aug;98(8):1725-33. doi: 10.1111/j.1572-0241.2003.07598.x. Am J Gastroenterol. 2003. PMID: 12907325 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters